1,2,3-substituted indolizine derivatives, inhibitors of...

Details 1,2,3-substituted indolizine derivatives, inhibitors of... 1,2,3-substituted indolizine derivatives, inhibitors of...

2003-04-02

2008-10-28

Seaman, D. Margaret (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S112000

Reexamination Certificate

active

07442708

ABSTRACT:
Compounds of formula I or salts thereof:in whichR1represents —OH, (C1-C5)alkoxy, carboxyl, (C2-C6)alkoxycarbonyl, —NR5R6, —NH—SO2-Alk, —NH—SO2-Ph, —NH—CO-Ph, —N(Alk)-CO-Ph, —NH—CO—NH-Ph, —NH—CO-Alk, —NH—CO2-Alk, —O—(CH2)n-cAlk, —O-Alk-COOR7, —O-Alk-O—R8, —O-Alk-OH, —O-Alk-C(NH2):NOH, —O-Alk-NR5R6, —O-Alk-CN, —O—(CH2)n-Ph, —O-Alk-CO—NR5R6, —CO—NH—(CH2)m—COOR7, —CO—NH-AlkR2represents H, (C1-C5)alkyl, (C1-C5)alkyl halide, (C3-C6)cycloalkyl or phenyl which is optionally substituted,A represents —CO—, —SO— or —SO2—,R3and R4which are identical or different, each represent H, (C1-C5)alkoxy, amino, carboxyl, (C2-C6)alkoxycarbonyl, —OH, nitro, hydroxyamino, -Alk-COOR7, —NR5R6, —NH-Alk-COOR7, —NH—COO-Alk, —N(R11)—SO2-Alk-NR9R10, —N(R11)—SO2-Alk, —N(R11)-Alk-NR5R6, —N(R11)—CO-Alk-NR9R10, —N(R11)—CO-Alk, —N(R11)—CO—CF3, —NH-Alk-HetN, —O-Alk-NR9R10, —O-Alk-CO—NR5R6, —O-Alk-HetN, or R3and R4form together a 5- to 6-membered unsaturated heterocycle, are inhibitors of basic fibroblast growth factors.

REFERENCES:
patent: 4378362 (1983-03-01), Rosseels
patent: 4400387 (1983-08-01), Rosseels
patent: 4499095 (1985-02-01), Russels et al.
patent: 4957925 (1990-09-01), Gubin et al.
patent: 7078209 (2006-07-01), Ledford et al.
patent: 2006/0199962 (2006-09-01), Alcouffe et al.
patent: 0 097 636 (1984-01-01), None
patent: 0 235 111 (1987-09-01), None
patent: WO 00 71129 (2000-11-01), None
patent: WO 00/71129 (2000-11-01), None
Zhang et al., Synthesis, “A one-step approach to 1-(fluoroalkyl)indolizine derivatives”, 1999, vol. 1, pp. 51-54.
Bora et al., Organic Letters, 2003, vol. 5, pp. 435-438.
Kakehi et al., Bulletin of the chemical society of Japan, 1996, vol. 69, pp. 1769-1776.
Wei et al., Journal of the chemical society, Perkin Transactions 1: Organic and Bio-organic chemistry, 1993, vol. 20, pp. 2487-2489.
Tamura et al., Journal of the chemical society, Perkin Transactions 1: Organic and Bio-organic chemistry, 1973, vol. 19, pp. 2091-2095.
Overzet et al., Journal of pharmaceutical and biomedical analysis, 1984, vol. 2, pp. 3-17.
Rosseels, et al., Study in the Indolizines Series. V. Effect of Indolizine Substitution i Position 1 in the Butoprozine Series, European J. of Med. Chemistry; 1983; 18(4); pp. 339-346.
Compounds for Screening, SPECS and bioSPECS XP002224380, Database Chemcats chemical abstracts service, Columbus, Ohio; Jul. 1, 2001.

Affiliated with

Also associated with

Rating

1,2,3-substituted indolizine derivatives, inhibitors of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 1,2,3-substituted indolizine derivatives, inhibitors of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,2,3-substituted indolizine derivatives, inhibitors of... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4013331